Medicines design Flashcards

1
Q

What is the sigmoidal behaviour of phosphofructokinase?

A
  • PFK-1 is the primary control enzyme of glycolysis.
  • It is composed of 4 subunits.
  • ATP is both a substrate and an allosteric effector:
  • High activity, Michaelis-Menten kinetics.
  • Low activity, Sigmoidal kinetics.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the 4 stages of the cori cycle?

A
  • Recycles R-lactate to glucose.
  • Lactate is transported from muscle to liver in blood.
  • Lactate dehydrogenase in liver converts R-lactate to pyruvate.
  • Pyruvate is converted to glucose by gluconeogenesis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How are glycolysis and gluconeogenesis regulated?

A

Both take place in the cytosol
Most enzymes are the same
Controlled by two processes
1. Energy levels in the cell (signalled by ATP)
2. Hormonal control (Signalled by fructose-2,6-bis-phosphate levels)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is the effect of glucagon on glycolysis and gluconeogenesis?

A
  • Glucagon is secreted in response to low blood glucose levels
  • Binding to a receptor initiates cAMP-mediated signalling.
  • This activates protein kinase A leading to pyruvate kinase and so activity of the glycolysis pathway is reduced.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the effect of insulin on glycolysis and gluconeogenesis?

A
  • Insulin has the opposite effect to glucagon
  • Secreted by pancreas in response to high blood glucose levels
  • In the fed state it increases the concentration of GLUT4 enabling uptake of glucose into muscle and adipose cells.
  • It counteracts the inhibitory effect of glucagon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the effect of adrenaline on glucose metabolism?

A
  • Adrenaline is a hormone produced in response to stress and exercise
  • The stress response requires glucose to be mobilised to generate ATP
  • Therefore, glycogen breakdown is stimulated, and glycogen synthesis is inhibited in a similar manner to glucagon (kinase-dependent phosphorylation of regulatory enzymes)
  • Glycolysis is stimulated and gluconeogenesis is inhibited
  • Increased activity of these pathways often occurs in ‘panic’ situations and therefore anaerobic respiration takes place.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the TCA cycle?

A
  • Pyruvate is converted to acetyl-CoA by pyruvate dehydrogenase complex
  • Oxaloacetate and acetyl-coA are condensed
  • Citrate is rearranged to isocitrate by cis-aconitase.
  • Isocitrate is oxidised and decarboxylates.
  • 2-Oxoglutarate is decarboxylated by the 2-OG dehydrogenase complex.
  • Succinyl-CoA is converted to succinate.
  • Desaturation and formation of FADH2.
  • Hydration.
  • Oxidation and formation of NADH.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is the TCA cycles regulated?

A
  • The primary control enzyme is pyruvate dehydrogenase complex.
  • High energy signals (ATP and NADH) and products of the TCA cycle are inhibitors.
  • Succinyl-CoA inhibits the activity of the α-ketoglutarate dehydrogenase complex (negative feedback control).
  • ADP (low energy signal) increases activity of isocitrate dehydrogenase.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the anapleurotic reaction?

A
  • Anaplerotic literally means ‘filling up’.
  • TCA cycle is used to provide starting materials for biosynthesis.
  • This results in depletion of oxaloacetate.
  • Acetyl-CoA accumulates.
  • High levels of acetyl-CoA decrease activity of pyruvate dehydrogenase complex.
  • High levels of acetyl-CoA increase activity of pyruvate carboxylase
  • Net effect is to rebalance oxaloacetate and acetyl-CoA levels.
  • Production of oxaloacetate is also important for gluconeogenesis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How is the TCA cycle regulated by the electron transport system?

A
  • The terminal acceptor for the system is dioxygen.
  • Under anaerobic conditions, the reduced electron acceptors in the transport system are not re-oxidized.
  • This means that the TCA cycle products NADH and FADH2 are not reoxidized to NAD+ and FAD.
  • This means that entry of pyruvate and flux through the TCA cycle is reduced.
  • Pyruvate is converted to lactate instead
  • Lactate is recycled via the Cori cycle
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

How is glycogen metabolism regulated?

A
  • Glucagon binds to its receptor, which produces cAMP.
  • This activates protein kinase A which phosphorylates target enzymes:
    • Phosphorylase kinase is activated.
    • This activates glycogen phosphorylase.
    • Glycogen synthase is inhibited.
    • More glucose is produced.
  • These effects are reversed by dephosphorylation by a phosphatase.
  • Insulin inhibits phosphorylation of glycogen synthase and maintains activity.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

How is fatty acid β-oxidation and biosynthesis regulated?

A
  • The key process is synthesis of malonyl-CoA.
  • High levels of malonyl-CoA allow fatty acid biosynthesis.
  • Malonyl-CoA inhibits import of fatty acids into mitochondria for degradation.
  • Glucagon phosphorylates acetyl-CoA carboxylase and reduces malonyl-CoA levels.
  • This inhibition can be overcome by high citrate levels.
  • Insulin promotes removal of phosphate from acetyl-CoA carboxylase.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is the overall effect of glucagon?

A
  • Glucagon increases blood glucose levels by cAMP-mediated activation of protein kinase A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the overall effect of insulin?

A
  • Insulin is secreted from the pancreas in response to high glucose blood levels. This causes:
    • Increased GLUT transporters in muscle and adipose tissue allowing glucose uptake.
    • It reduces phosphorylation of glycogen synthase and glycogen phosphorylase, promoting glycogen synthesis.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the effect of glucocorticoids on glucose and lipid metabolism?

A
  • High levels of glucocorticoids promotes biosynthesis of gluconeogenic enzymes and suppresses production of glycolytic enzymes.
  • There also appears to be a direct activation of gluconeogenic enzymatic activity in some circumstances.
  • There is also a complex effect on fatty acid metabolism. These effects interact with that of insulin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How are ketone bodies formed?

A
  • In diabetes or starvation glucose is scarce.
  • Brain and erythrocytes are particularly dependent on glucose for energy.
  • Fatty acids are kept in adipose tissue and are not easy to transport around the blood so are converted to acetyl-CoA.
  • Three molecules of acetyl-CoA are used to acetoacetate and 3-hydroxybutyrate (a.k.a. ketone bodies) by the mevalonic acid pathway
  • These are distributed by the blood and can be used as fuels instead of glucose.
  • Acetoacetate is easily converted to acetone, hence the solvent smell on the breath of diabetics experiencing hyperglycaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are glycation reactions?

A
  • Glycation is the non-enzymatic reaction of glucose with nucleophilic groups.
  • Derivatives can further react to produce advanced glycation products (AGPs).
  • Glycation of haemoglobin is often used to measure glucose control in diabetic and other patients.
  • Glycation of haemoglobin A gives haemoglobin A1c, status reflects glucose control over the last 3 months:
    Normal patients HbA1c = < 6% (<48 mmol/mol).
    Uncontrolled diabetes = > 10% (>86 mmol/mol).
    Target for type 1 diabetes < 7.5% (<58 mmol/mol)
    Target for type 2 diabetes < 6.5% (<48 mmol/mol).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are monosaccharides?

A
  • Carbohydrates are hydroxylated derivatives of aldehydes and ketones.
  • Complex carbohydrates are built from monosaccharides ‘building blocks’.
  • Aldohexose possess aldehyde groups, ketohexoses possess ketone groups.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are hexose monosaccharides?

A
  • Most monosaccharides have D- configuration (the OH on carbon-5 is on the right hand side)
  • The remaining three stereochemical centres can have variable configurations – hence 8 possible isomers.
  • Glucose is the most abundant hexose.
  • Galactose and mannose are epimers of glucose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the ring closure reaction of glucose?

A
  • Addition of alcohol group to aldehyde forms a hemiacetal
  • Presence of OH group on carbon-5 means a 6 membered ring is formed (favourable).
  • A new chiral centre is formed on hemiacetal formation, which can have one of two configurations (α- or β-) (down or out the side, respectively).
  • These new isomers are called anomers.
  • Ring-opened and ring closed forms are in dynamic equilibrium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are reducing sugars?

A
  • Glycation can only occur with reducing sugars
  • Reducing sugars reduce Cu2+ and Ag+ ions in basic solution and are themselves oxidised
  • Ketoses undergo tautomerisation to aldehydes in alkali solution and so are also reducing.
  • Reducing sugars (primarily glucose) are responsible for protein and lipid glycation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the glycation of proteins?

A

the spontaneous, non-enzymatic reaction of proteins with simple reducing sugars and related metabolites.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the amadori reaction?

A
  • Excess glucose can react with amino groups of intracellular and extracellular proteins in a nonenzymatic manner to form glycated residues termed as Amadori products
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What are other types of glycation?

A
  • Glycation can occur with other proteins, including serum proteins such as albumin, and α-crystallins
  • The most common residue to be glycated is lysine.
  • Lysine residues in a particular protein are not glycated to the same extent.
  • Other protein residues (e.g., Arg, His, Trp and Cys and the N-terminal amine) can be glycated. Nucleophilic residues will also react with the initial Amadori product to produce Advanced Glycation Products (AGPs).
  • Cross-linking of protein strands and reaction with other nucleophiles can occur.
  • Glycation also occurs with lipids containing amine groups, such as phosphotidylethanolamine (a phospholipid found in cell membranes) and low density lipoprotein (a blood particle used to transport cholesterol around the body).
  • Glycation with other reducing sugars e.g., lactose, fructose also possible.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What are the consequences of glycation?

A
  • Glycation is recognised as a major cause of diabetic secondary complications, including nephropathy, retinopathy and diabetic cataracts and atherosclerosis.
  • Glycated proteins are difficult to degrade, so there is a build-up of damaged proteins in the cell.
  • Damage results in production of auto-antibodies, resulting in increased levels of inflammation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

How do you measure glycation?

A
  • Several analytical techniques can be used to measure early glycation products including:
    • Ion-exchange chromatography.
    • Affinity chromatography or gel electrophoresis
    • Immunoassays such as ELISA which detect specific antigens.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Which 3 three drugs have we got from nature?

A

Exenatide (gila monsters)

Aspirin (trees)

Digoxin (plants)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the bioactive peptides from Gila monsters?

A

Exendins are of interest in the treatment of diabetes (especially Exendin-4)

Named as they were extracted from EXocrine glands and ENDocrine actions - EXENDIN

The Structure of Exendin-4 is similar to a human peptide – Glucagon-Like Peptide -1 or GLP-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What is GLP-1?

A
  • GLP-1 is a peptide hormone
  • Primarily produced in the intestine
  • GLP-1 is cleaved into two active peptides
  • Dipeptidyl peptidase-4 (DPP-4) cleaves the GLP peptides
  • Greatest density of GLP-1 receptors in the pancreas but also found in many other sites including the CNS and stomach
30
Q

What are the 3 food related actions of GLP-1?

A

1) Stimulate insulin release

2) Inhibit glucagon release

3) Slow gastric emptying

31
Q

How was semaglutide made into an oral formulation?

A
  • Peptides are generally unsuitable for oral delivery
  • Adding sodium N-(8-[2-hydroxybenzoyl] amino)caprylate – SNAC to the formulation of semaglutide helps to increase pH and increases membrane permeability to aid absorption
32
Q

How was digoxin discovered?

A

Digoxin is a cardiac glycoside

Conjugate of steroid aglycone and 3 x sugar moiety

Consider function of the sugars, adding to MW but increasing bioactivity

Much trial and error to find the correct dose in micrograms

33
Q

What is the 3D shape of Digoxin?

A

3D structure of digoxin, and other steroids, relates to function
Croissant!

34
Q

How does the structure of digoxin aid its function?

A
  • Structure allows it to inhibit sodium pumps in myocardial cells
  • This increases calcium in the cells and results in increase in contractile force
  • Also slows heart rate - bradycardic
35
Q

What is digoxin used for?

A
  • Bradycardic and positive inotropic effects mean digoxin is useful in AF and heart failure
  • Heart failure symptoms – SOB, oedema, TATT
  • AF symptoms – palpitations, chest pain, fatigue
36
Q

What is lipinski’s rule of 5?

A

Molecular weight of less than 500 Da

No more than 5 H-bond donor groups

No more than 10 H-bond acceptor groups

LogP of less than +5

37
Q

What are the functions of cholesterol?

A
  • Strengthens lipid bilayer
  • It is the precursor of several hormones
  • HMG-CoA Reductase is a key enzyme in cholesterol synthesis – the target of statins
38
Q

What are the important functions of vit D?

A
  • Regulation of plasma calcium, mainly via increasing absorption, decreasing excretion and mobilising from bone
  • Regulation of plasma phosphate – absorption and excretion
  • Immune functions
  • 1 microgram Vitamin D = 40 IU
  • 10mcg for housebound
39
Q

What is testosterone?

A
  • Male sex hormone
  • Leads to secondary sexual characteristics, motility of sperm
  • Biosynthesised from progesterone
  • Secondary alcohol on D-ring, rather than ketone
40
Q

What is estrone?

A
  • Estrone is a weak oestrogen
  • Useful in the synthesis of other molecules
  • Carbonyl at C17 is susceptible to attack
41
Q

What is estradiol?

A
  • One of the female sex hormones
  • Used in HRT
  • Quite similar in structure to testosterone
42
Q

What is ethinylestradiol?

A
  • Synthetic derivative of estradiol
  • More resistant to metabolism compared to estradiol
  • Better oral activity compared to estradiol
43
Q

What is cholic acid?

A
  • Derived from cholesterol
  • Water soluble (RCOOH)
  • Amphiphilic molecule (One side is hydrophilic, one side is hydrophobic)
  • Useful for dissolving fats via formation of micelles
44
Q

What makes T1DM an autoimmune disease?

A
  • Characterized by immune-mediated destruction of the insulin-secreting b cells of the pancreas
  • T-cell mediated autoimmune disease with circulating autoantibodies to various islet cell antigens
  • Auto-antibodies to insulin (IAA), glutamic acid decarboxylase (GADA), islet cell cytoplasm, zinc transporter and protein tyrosine phosphatase have all been identified
45
Q

What causes T2DM?

A
  • The body cannot produce enough insulin OR the body cannot respond to insulin
  • Used to appear in people > 40 yrs of age but younger people are increasingly diagnosed with the condition
  • Can go undiagnosed for a long time
  • Accounts for between 85-95% of all people with diabetes
46
Q

What are the three types of insulins and what are they used for?

A

Short-acting insulins – before meals
Intermediate-acting insulins – once or twice daily, before meals
Long-acting insulins – once or twice daily, before meals

47
Q

How does insulin affect metabolism?

A

Insulin stimulates glucose utilisation via glycolysis and glycogenesis

Insulin inhibits glucose production by inhibiting gluconeogenesis and glycogenolysis

Insulin is an important regulator of glucose, lipid and protein metabolism. It suppresses hepatic glucose and triglyceride production, inhibits adipose tissue lipolysis and whole-body and muscle proteolysis and stimulates glucose uptake in muscle

48
Q

What are a-glucosidase inhibitors?

A
  • Reduces the digestion of complex carbohydrates, slows their absorption from the gut
  • Reduces postprandial glycaemia
  • Adverse effects are common – flatulence and diarrhoea – high discontinuation rate
  • Acarbose is itself an oligosaccharide, metabolized in the intestines by enzymes and bacteria
  • Used where other oral hypoglycaemics are not tolerated
49
Q

What is Carbohydrate hydrolysis in the gut?

A
  • Acarbose is a high affinity reversible inhibitor of alpha glucosidase so reduces the availability of absorbable sugars
  • 30-35% reduction in postprandial rise in blood glucose
  • Also reduced insulin secretion, GIP and triglycerides, and delayed GLP-1 rise (incretins)
  • Does not cause hypoglycaemia (monotherapy), hyperinsulinemia or weight gain
50
Q

What are SGLT2 inhibitors?

A
  • Reversibly inhibit sodium glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion
  • Kidney plays a key role in regulating glucose homeostasis
  • In a non-diabetic person, virtually all of the glucose filtered is reabsorbed, and none appears in the urine.
  • Presence of glucose in the urine is a marker for diabetes
  • Glycosuria following SGLT2 inhibition involves lowering of the renal glucose excretion threshold, which functions to reduce hyperglycaemia
  • Patients with T2DM express a significantly higher number of SGLT2 and GLUT2 than healthy individuals in PCT and renal glucose uptake is also elevated
  • Possible risk of more urinary tract infections
51
Q

What are Sulfonylureas?

A

“Insulin secretagogues” – stimulate insulin secretion - hypoglycaemic

52
Q

What are the potential adverse effects of sulfonylureas?

A
  • Major adverse side effect is hypoglycaemia:
    • More common in elderly/renal/hepatic impaired patients
  • May stimulate weight gain because of effects of insulin to promote fat storage
  • Patients may go on to develop secondary pancreatic b-cell failure
53
Q

What are Meglitanides?

A
  • “nonsulfonylureas” oral hypoglycaemic agents
  • “Insulin secretagogues” – act by blockade of KATP channels
  • More rapidly absorbed than sulfonylureas so faster onset of action
  • Peak insulin levels occur within 60 min – must be taken 1-30 min before meal
  • Returning to pre-drug level before the next meal
  • May be used in combination with metformin, not widely used
54
Q

What are GLP1 agonists (incretins)?

A
  • Incretin hormones are released in the GI tract postprandially to simulate glucose-induced insulin release from the pancreas.
  • GLP-1 and gastric inhibitory polypeptide are “incretins”
  • GLP-1 affects insulin biosynthesis and secretion, only under hyperglycaemic conditions
  • GLP-1 inhibits glucagon release and is a satiety signal leading to a reduction in food intake
  • GLP-1 levels are reduced in T2DM
  • Main adverse effect is nausea which deters use
  • GLP-1 therapy is aimed at overweight T2DM patients
55
Q

What are Gliptins (DPP-4 inhibitors)?

A
  • Dipeptidyl peptidase (DPP-4) is the enzyme responsible for rapid degradation of GLP-1
  • Blockade of DPP-4 potentiates the actions of endogenous GLP-1
  • Effects are to enhance insulin secretion, suppress glucagon secretion and slowed gastric emptying
56
Q

What are Biguanides?

A
  • Acts only in the presence of endogenous insulin – an insulin-sensitizing drug
  • The only available biguanide is metformin (1957)
  • Drug of choice in overweight patients
57
Q

What is the antihyperglycaemic MOA of metformin?

A
  • Main action is to decrease hepatic glucose production by inhibiting gluconeogenesis
  • Stimulates insulin receptor expression and tyrosine kinase activity (insulin sensitizing)
  • Stimulates glucose uptake and utilization in skeletal muscle
58
Q

What are the 6 benefits of metformin?

A
  • Lack of weight gain
  • No increase in plasma insulin, and resultant hypoglycaemia
  • Persistent efficacy (2-5 yrs) when used alone or in combination
  • Positive changes in lipid profiles (decreased TGs, increased HDL)
  • Reduction of blood pressure
  • Delay in moving to insulin injections
59
Q

What are the potential side effects of metformin?

A
  • GI upset and alterations
  • Lactic acidosis can occur, more likely in renal impairment
  • Not metabolized in the liver, but excreted via kidney so drugs that are eliminated by tubular secretion may compete with metformin for elimination and cause clinically significant interactions
60
Q

What is Lactic acidosis caused by metformin?

A
  • Occurs because of excessive lactate production because of blockade of mitochondrial respiratory chain complex 1
  • Coupled with impaired hepatic metabolism can result in sustained lactate accumulation
61
Q

What are Thiazolidinediones?

A
  • “Insulin-sensitizing” drug
  • Pioglitazone
  • Rapidly absorbed after oral administration and most of the drugs are excreted unchanged in the faeces – therefore renal impairment does not affect drug blood levels
62
Q

What are the potential side effects of Thiazolidinediones?

A
  • Minimal hypoglycaemia (monotherapy)

No evidence of drug-induced hepatoxicity with rosiglitazone and pioglitazone (but problem for troglitazone)

  • Weight gain is major side effect – but subcutaneous fat, rather than visceral fat, less harmful
  • Glitazones are rapidly absorbed from the GI tract, extensively bound by plasma proteins and metabolized by cytrochrome P450 enzymes to active metabolites
63
Q

What is SWOT analysis of peptide and protein therapeutics?

A
  • strengths
  • weaknesses
  • opportunities
  • threats
64
Q

What are the best ways to analyse proteins?

A

Depending on the substance, identification may be by spectroscopic methods (IR, NMR, MS),
chromatograpy (HPLC), amino acid analysis, or peptide mapping.

Reversed phase HPLC (RP-HPLC) is particularly suitable for peptides

65
Q

What is the structure of insulin?

A

2-chain peptide consisting of 51amino acids (MW = 5808 Da):
- Chain A = 21amino acids
- Chain B = 30 amino acids
- Contains 2 x interchain disulfde bonds (A7→ B7; A20→ B19)
- 1 x intrachain disulfide (A6 → A11)

66
Q

What is peptide mapping?

A
  • An identity test for peptides and proteins.
  • Chemical or enzymatic cleavage of the peptide backbone in specific locations generates a set of fragments, which upon separation (chromatography) and identification (MS) provide a “fingerprint”.
  • Allows large peptides differing in only one or two amino acids to be distinguished.
  • Important for the identification and quality control of peptide and protein natural products
  • Enzymes used in peptide mapping recognise and bind peptides with a specific amino acid (amino acid side chain) at one side of the peptide bond that is hydrolysed
67
Q

How were incretins and incretin-mimetics developed?

A
  • Incretins = gastrointestinal hormones that increase insulin release from the pancreas in response to elevated serum glucose levels.
  • Most important examples are GIP and GLP-1
  • Activation of the incretin system is rapid, but inactivation is even faster
  • Patients with T2DM produce normal levels of GIP, but show lower sensitivity, while GLP-1 maintains its full efficacy, but is produced to a lesser extent.

2 therapeutic strategies
- Develop incretin mimetics (analogues of GLP-1) with extended plasma t1/2
- Prevent the inactivation of both incretins (GIP and GLP-1)

68
Q

What are the 4 classes of proteases?

A

SERINE PROTEASES (DPP-4)
CYSTEINE PROTEASES
ASPARTIC PROTEASES (pepsin, renin)
METALLOPROTEASES (ACE)

69
Q

How do you design an inhibitor of a serine protease?

A
  • Start with a natural substrate, identify the peptide bond that is hydrolysed by the enzyme.
  • Replace the peptide structure on the C-terminal side of the bond that will be hydrolysed with a reactive group (a “warhead”) that can interact directly with the enzyme’s active site nucleophile.
  • DPP-4 hydrolyses peptide bonds after the dipeptide unit Xaa-Ala, or Xaa-Pro
70
Q

Why is Phlorizin unstable?

A

Phlorizin is an acetal
Formation of acetals from a hemiacetal and an alcohol (or phenol) is reversible.
Hydrolysis (the reverse reaction) occurs with acid catalysis.

Conclusions from SAR:
- C-glycoside required
- Aromatic ring attached to the sugar component is very desirable
- Considerable scope to vary the aglycone
- Not much value in varying sugar (ease of synthesis)??

70
Q

What are SGLT2 inhibitors?

A

A new family of natural product-inspired antihyperglycemic agents.

SGLT2 plays an important role in controlling glucose homeostasis in the kidney.

Inhibition of SGLT2 therefore recognised as a potential therapeutic target for
treatment of T2DM.
Initial lead effective at lowering glucose levels in animal models, but not suitable for
development due to lack of stability, and lack of selectivity vs SGLT1.